Ketoconazole Articles

CHICAGO, IL USA (UroToday.com) - Presented by Won Kim, John Wilton, Li Zhang, Amy M. Lin, Lawrence Fong, Andrew Caleb Hsieh, Terence W. Friedlander, Rahul Raj Aggarwal, Vivian K. Weinberg, Allison Morse, Jeffrey Bozeman, Arturo Molina, Gerald J. Fetterly, James Mohler, Russell Zelig Szmulewitz, Eric Jay Small, and Charles J. Ryan at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

Ketoconazole has long been the first-line medical therapy for controlling hypercortisolism secondary to either pituitary or adrenal pathology. However, it is largely unavailable in most countries. As a result, we have turned to fluconazole as a viable alternative in view of its favourable safety profile.

BERKELEY, CA (UroToday.com) - Prostate cancer is the second most common cancer among men, with almost 240 000 cases expected to be diagnosed in 2013.^[1]

Background Ketoconazole (Keto), an antifungal drug and a common therapeutic option in the treatment of advanced prostate cancer, is known to cause reproductive dysfunctions. Like Keto, melatonin has antifungal and anticarcinogenic actions.